AstraZeneca AB in agreement with the European Medicines Agency and the <National Competent Authority > would like to inform you of the following:

Summary

• A causal relationship between the vaccination with Vaxzevria and the occurrence of thrombosis in combination with thrombocytopenia is considered plausible.
• Although such adverse reactions are very rare, they exceeded what would be expected in the general population.
• No specific risk factors have been identified at this stage.
• Healthcare professionals should be alert to the signs and symptoms of thromboembolism and or thrombocytopenia and inform vaccinees accordingly. 
• The use of this vaccine should be in accordance with official national recommendations.